About NuCana
NuCana (NASDAQ:NCNA) is a biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its proprietary ProTide technology to transform some of the most widely used chemotherapy agents into more effective and safer medicines. While primarily listed on the NASDAQ stock exchange, this innovative firm is dedicated to advancing a broad and deep pipeline, centered around transformative oncology drug candidates. Their projects aim to tackle various cancer types, with an ongoing commitment to both research and development in striving to meet unmet medical needs within the oncology space. NuCana's objectives are clearly defined around pushing the boundaries of what current treatments can achieve, aiming to offer new hope and possibilities for patients facing cancer.
Snapshot
Operations
Products and/or services of NuCana
- Acelarin, a nucleotide analogue designed for the treatment of various cancers, including ovarian, pancreatic, and biliary.
- NUC-3373, a next-generation fluoropyrimidine aimed at enhancing treatment for colorectal cancer and other solid tumors.
- NUC-7738, a novel compound transforming a naturally occurring nucleoside into a potential treatment for hematological and solid cancers.
- Development of proprietary ProTide technology, enhancing anti-cancer agents' efficacy by bypassing resistance mechanisms.
- Collaboration with major pharmaceutical and research institutions for the advancement of oncology treatments.
- Ongoing clinical trials assessing the effectiveness and safety of their leading compounds in various stages of development.
NuCana executive team
- Mr. Andrew Martin Kay B. PharmIndependent Executive Chairman of the Board
- Mr. Hugh Stephen GriffithFounder, CEO & Executive Director
- Prof. David HarrisonHead of Translational Medicine & Studies
- Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical Officer
- Mr. Ian WebsterInterim Chief Financial Officer
- Ms. Theresa BruceChief Operating Officer
- Mr. Gordon KennovinSenior VP of CMC & Development
- Dr. Stuart GrantSenior Vice President of Regulatory Affairs
- Mr. Martin Alexander QuinnCompany Secretary